Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum
Open accessPublished version of a preprint
Abstract
Abstract On August 30, 2021, the WHO classified the SARS-CoV-2 Mu variant (B.1.621 lineage) as a new variant of interest. The WHO defines “comparative assessment of virus characteristics and public health risks” as primary action in response to the emergence of new SARS-CoV-2 variants. Here, we demonstrate that the Mu variant is highly resistant to sera from COVID-19 convalescents and BNT162b2-vaccinated individuals. Direct comparison of different SARS-CoV-2 spike proteins revealed that Mu spike is more resistant to serum-mediated neutralization than all other currently recognized variants of interest (VOI) and concern (VOC). This includes the Beta variant (B.1.351) that has been suggested to represent the most resistant variant to convalescent and vaccinated sera to date (e.g., Collier et al, Nature, 2021; Wang et al, Nature, 2021). Since breakthrough infection by newly emerging variants is a major concern during the current COVID-19 pandemic (Bergwerk et al., NEJM, 2021), we believe that our findings are of significant public health interest. Our results will help to better assess the risk posed by the Mu variant for vaccinated, previously infected and naïve populations.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
R346K is the defining mutation for the B.1.621/Mu variant.
“which is the defining mutation for the B.1.621/Muvariant 27”
From Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
SARS-CoV-2 variants, spike mutations and immune escape
Harvey, W. T., Carabelli, A. M., Jackson, B., Gupta, R. K., Thomson, E. C., Harrison, E. M., Ludden, C., Reeve, R., Rambaut, A., COVID-19 Genomics UK (COG-UK) Consortium, et al. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-021-00573-0 · Cited by 3,528 · see citing works
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · see citing works
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729 · see citing works
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728 · see citing works
Vaccine Breakthrough Infections with SARS-CoV-2 Variants
Hacisuleyman, E., Hale, C., Saito, Y., Blachere, N. E., Bergh, M., Conlon, E. G., Schaefer-Babajew, D. J., DaSilva, J., Muecksch, F., Gaebler, C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105000 · Cited by 716 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290 · see citing works
Fiolet, T., Kherabi, Y., MacDonald, C.-J., Ghosn, J., & Peiffer-Smadja, N. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.10.005 · Cited by 911 · see citing works
Tarke, A., Coelho, C. H., Zhang, Z., Dan, J. M., Yu, E. D., Methot, N., Bloom, N. I., Goodwin, B., Phillips, E., Mallal, S., et al. (2022) · Cell · doi:10.1016/j.cell.2022.01.015 · Cited by 858 · see citing works
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Suzuki, R., Yamasoba, D., Kimura, I., Wang, L., Kishimoto, M., Ito, J., Morioka, Y., Nao, N., Nasser, H., Uriu, K., et al. (2022) · Nature · doi:10.1038/s41586-022-04462-1 · Cited by 655 · see citing works
Self-citationActivity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J. J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/s41586-022-04399-5 · Cited by 456 · see citing works
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440 · see citing works
Lu, L., Mok, B. W.-Y., Chen, L. L., Chan, J. M. C., Tsang, O. T. Y., Lam, B. H. S., Chuang, V. W., Chu, A. W., Chan, W. M., Ip, J. D., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab1041 · Cited by 390 · see citing works
Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike
Yamasoba, D., Kimura, I., Nasser, H., Morioka, Y., Nao, N., Ito, J., Uriu, K., Tsuda, M., Zahradník, J., Shirakawa, K., et al. (2022) · Cell · doi:10.1016/j.cell.2022.04.035 · Cited by 366 · see citing works
Self-citationTamura, T., Ito, J., Uriu, K., Zahradník, J., Kida, I., Anraku, Y., Nasser, H., Shofa, M., Oda, Y., Lytras, S., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38435-3 · Cited by 330 · see citing works
Self-citationVirological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5
Kimura, I., Yamasoba, D., Tamura, T., Nao, N., Suzuki, T., Oda, Y., Mitoma, S., Ito, J., Nasser, H., Zahradník, J., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.018 · Cited by 286 · see citing works
Self-citationSARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive immune escape
Cele, S., Karim, F., Lustig, G., San, J. E., Hermanus, T., Tegally, H., Snyman, J., Moyo-Gwete, T., Wilkinson, E., Bernstein, M. P., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.01.005 · Cited by 230 · see citing works
The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines
McLean, G. R., Kamil, J. P., Lee, B., Moore, P. L., Schulz, T. F., Muik, A., Şahin, U., Türeci, Ö., & Pather, S. (2022) · mBio · doi:10.1128/mbio.02979-21 · Cited by 190 · see citing works
Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
Saito, A., Tamura, T., Zahradník, J., Deguchi, S., Tabata, K., Anraku, Y., Kimura, I., Ito, J., Yamasoba, D., Nasser, H., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.003 · Cited by 186 · see citing works
Self-citationThe Evolution and Biology of SARS-CoV-2 VariantsPreprint
Telenti, A., Hodcroft, E. B., & Robertson, D. L. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041390 · Cited by 183 · see citing works
Antigenic cartography of SARS-CoV-2 reveals that Omicron BA.1 and BA.2 are antigenically distinct
Mykytyn, A. Z., Rissmann, M., Kok, A., Rosu, M. E., Schipper, D., Breugem, T. I., van den Doel, P. B., Chandler, F., Bestebroer, T., de Wit, M., et al. (2022) · Science Immunology · doi:10.1126/sciimmunol.abq4450 · Cited by 153 · see citing works
An antibody-escape estimator for mutations to the SARS-CoV-2 receptor-binding domain
Greaney, A. J., Starr, T. N., & Bloom, J. D. (2022) · Virus Evolution · doi:10.1093/ve/veac021 · Cited by 147 · see citing works
Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant
Ito, J., Suzuki, R., Uriu, K., Itakura, Y., Zahradník, J., Kimura, K., Deguchi, S., Wang, L., Lytras, S., Tamura, T., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38188-z · Cited by 146 · see citing works
Self-citationAntibody-mediated neutralization of SARS-CoV-2
Gruell, H., Vanshylla, K., Weber, T., Barnes, C. O., Kreer, C., & Klein, F. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.005 · Cited by 145 · see citing works
Molecular characteristics, immune evasion, and impact of SARS-CoV-2 variants
Sun, C., Xie, C., Bu, G., Zhong, L., & Zeng, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01039-2 · Cited by 139 · see citing works
Ao, D., He, X., Hong, W., & Wei, X. (2023) · MedComm · doi:10.1002/mco2.239 · Cited by 128 · see citing works
Christensen, P. A., Olsen, R. J., Long, S. W., Subedi, S., Davis, J. J., Hodjat, P., Walley, D. R., Kinskey, J. C., Saavedra, M. O., Pruitt, L., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.10.019 · Cited by 126 · see citing works
SARS-CoV-2: Evolution and Emergence of New Viral Variants
Flores-Vega, V. R., Monroy-Molina, J. V., Jiménez-Hernández, L. E., Torres, A. G., Santos, J. I., & Rosales-Reyes, R. (2022) · Viruses · doi:10.3390/v14040653 · Cited by 121 · see citing works
Zabidi, N. Z., Liew, H. L., Farouk, I. A., Puniyamurti, A., Yip, A. J. W., Wijesinghe, V. N., Low, Z. Y., Tang, J. W.-T., Chow, V. T. K., & Lal, S. K. (2023) · Viruses · doi:10.3390/v15040944 · Cited by 121 · see citing works
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron
Carreño, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A. J., Kawabata, H., Sominsky, L. A., Clark, J., Adelsberg, D. C., Bielak, D. A., et al. (2021) · Nature · doi:10.1038/d41586-021-03846-z · Cited by 112 · see citing works
Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions
Abulsoud, A. I., El‐Husseiny, H. M., El-Husseiny, A. A., El‐Mahdy, H. A., Ismail, A., Elkhawaga, S. Y., Khidr, E. G., Fathi, D., Mady, E. A., Najda, A., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113977 · Cited by 108 · see citing works
Virological characteristics of the SARS-CoV-2 BA.2.86 variant
Tamura, T., Mizuma, K., Nasser, H., Deguchi, S., Padilla‐Blanco, M., Oda, Y., Uriu, K., Tolentino, J. E., Tsujino, S., Suzuki, R., et al. (2024) · Cell Host & Microbe · doi:10.1016/j.chom.2024.01.001 · Cited by 108 · see citing works
Self-citationBravo, L. C., Smolenov, I. V., Han, H. H., Li, P., Hosain, R., Rockhold, F. W., Clemens, S. A. C., Roa, C. C., Borja-Tabora, C., Quinsaat, A., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00055-1 · Cited by 104 · see citing works
Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant
Tamura, T., Irie, T., Deguchi, S., Yajima, H., Tsuda, M., Nasser, H., Mizuma, K., Plianchaisuk, A., Suzuki, S., Uriu, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45274-3 · Cited by 103 · see citing works
Self-citationPopulation immunity predicts evolutionary trajectories of SARS-CoV-2
Meijers, M., Ruchnewitz, D., Eberhardt, J., Łuksza, M., & Lässig, M. (2023) · Cell · doi:10.1016/j.cell.2023.09.022 · Cited by 97 · see citing works
Song, J. Y., Choi, W. S., Heo, J. Y., Lee, J. S., Jung, D. S., Kim, S., Park, K., Eom, J. S., Jeong, S. J., Lee, J., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101569 · Cited by 93 · see citing works
SARS-CoV-2 evolution on a dynamic immune landscape
Raharinirina, N. A., Gubela, N., Börnigen, D., Smith, M. R., Oh, D., Budt, M., Mache, C., Schillings, C., Fuchs, S., Dürrwald, R., et al. (2025) · Nature · doi:10.1038/s41586-024-08477-8 · Cited by 86 · see citing works
Bekliz, M., Adea, K., Vetter, P., Eberhardt, C. S., Hosszu-Fellous, K., Vu, D., Puhach, O., Essaidi-Laziosi, M., Waldvogel‐Abramowski, S., Stephan, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31556-1 · Cited by 85 · see citing works
Newman, J., Thakur, N., Peacock, T. P., Bialy, D., Elrefaey, A. M. E., Bogaardt, C., Horton, D. L., Ho, S., Kankeyan, T., Carr, C., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01163-3 · Cited by 85 · see citing works
Liu, H., Wei, P., Kappler, J. W., Marrack, P., & Zhang, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.825256 · Cited by 79 · see citing works
On the Origins of Omicron’s Unique Spike Gene Insertion
Venkatakrishnan, A., Anand, P., Lenehan, P. J., Suratekar, R., Raghunathan, B., Niesen, M. J. M., & Soundararajan, V. (2022) · Vaccines · doi:10.3390/vaccines10091509 · Cited by 73 · see citing works
Seephetdee, C., Bhukhai, K., Buasri, N., Leelukkanaveera, P., Lerdwattanasombat, P., Manopwisedjaroen, S., Phueakphud, N., Kuhaudomlarp, S., Olmedillas, E., Saphire, E. O., et al. (2022) · Antiviral Research · doi:10.1016/j.antiviral.2022.105370 · Cited by 71 · see citing works
Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R., Coggins, S., et al. (2022) · doi:10.1101/2022.07.05.498883 · Cited by 68 · see citing works
Ikemura, N., Taminishi, S., Inaba, T., Arimori, T., Motooka, D., Katoh, K., Kirita, Y., Higuchi, Y., Li, S., Suzuki, T., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn7737 · Cited by 61 · see citing works
Wang, W., Lusvarghi, S., Subramanian, R., Epsi, N. J., Wang, R., Goguet, E., Fries, A. C., Echegaray, F., Vassell, R. A., Coggins, S. A., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.012 · Cited by 59 · see citing works
Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape
Lou, F., Li, M., Pang, Z., Jiang, L., Guan, L., Tian, L., Hu, J., Fan, J., & Fan, H. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.744242 · Cited by 53 · see citing works
SARS-CoV-2: phenotype, genotype, and characterization of different variants
Saberiyan, M., Karimi, E., Khademi, Z., Movahhed, P., Safi, A., & Ghahfarrokhi, A. M. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00352-6 · Cited by 52 · see citing works
Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma
Wang, Y.-D., Ma, Y., Xu, Y., Liu, J., Li, X., Chen, Y., Chen, Y., Xie, J., Xiao, L., Xiang, Z., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2027219 · Cited by 50 · see citing works
The SARS-CoV-2 spike S375F mutation characterizes the Omicron BA.1 variant
Kimura, I., Yamasoba, D., Nasser, H., Zahradník, J., Kosugi, Y., Wu, J., Nagata, K., Uriu, K., Tanaka, Y., Ito, J., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105720 · Cited by 50 · see citing works
Self-citationYamamoto, M., Gohda, J., Kobayashi, A., Tomita, K., Hirayama, Y., Koshikawa, N., Seiki, M., Semba, K., Akiyama, T., Kawaguchi, Y., et al. (2022) · mBio · doi:10.1128/mbio.00519-22 · Cited by 47 · see citing works
The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection
Moga, E., Lynton‐Pons, E., & Domingo, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904686 · Cited by 46 · see citing works
Desmecht, S., Tashkeev, A., Moussaoui, M. E., Maréchal, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863554 · Cited by 45 · see citing works
García-Valtanen, P., Hope, C. M., Masavuli, M. G., Yeow, A. E. L., Balachandran, H., Mekonnen, Z. A., Al-Delfi, Z., Abayasingam, A., Agapiou, D., Stella, A. O., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100651 · Cited by 42 · see citing works
Queirós-Reis, L., da Silva, P. G., Gonçalves, J., Brancale, A., Bassetto, M., & Mesquita, J. R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910836 · Cited by 39 · see citing works
Liu, H., Wei, P., Zhang, Q., Aviszus, K., Linderberger, J., Yang, J. J., Liu, J., Chen, Z., Waheed, H., Reynoso, L., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911325 · Cited by 39 · see citing works
Variants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Vaccine Effectiveness
Tulimilli, S. V., Dallavalasa, S., Basavaraju, C. G., Rao, V. K., Chikkahonnaiah, P., Madhunapantula, S. V., & Veeranna, R. P. (2022) · Vaccines · doi:10.3390/vaccines10101751 · Cited by 37 · see citing works
Ju, B., Zheng, Q., Guo, H., Fan, Q., Li, T., Song, S., Sun, H., Shen, S., Zhou, X., Cheng, L., et al. (2022) · Cell Research · doi:10.1038/s41422-022-00638-6 · Cited by 37 · see citing works
Antigenic evolution of SARS coronavirus 2
Mykytyn, A. Z., Fouchier, R. A. M., & Haagmans, B. L. (2023) · Current Opinion in Virology · doi:10.1016/j.coviro.2023.101349 · Cited by 36 · see citing works
Mohandas, S., Yadav, P. D., Sapkal, G. N., Shete, A. M., Deshpande, G. R., Nyayanit, D. A., Patil, D. Y., Kadam, M., Kumar, A., Mote, C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103997 · Cited by 35 · see citing works
Lineage-mosaic and mutation-patched spike proteins for broad-spectrum COVID-19 vaccine
Wu, Y., Wang, S., Zhang, Y., Yuan, L., Zheng, Q., Wei, M., Shi, Y., Wang, Z., Ma, J., Wang, K., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.10.011 · Cited by 35 · see citing works
Ikemura, N., Hoshino, A., Higuchi, Y., Taminishi, S., Inaba, T., & Matoba, S. (2021) · medRxiv · doi:10.1101/2021.12.13.21267761 · Cited by 34 · see citing works
Xie, X., 中国科学院昆明动物研究所中国科学院动物模型与人类疾病机理重点实验室, 中.-香., Han, J.-B., Ma, G., Feng, X., Li, X., Zou, Q., Deng, Z., Zeng, J., 中国科学院昆明动物研究所国家昆明高等级生物安全灵长类动物实验中心, 生., et al. (2021) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2021.343 · Cited by 31 · see citing works
Baker, D., MacDougall, A. M., Kang, A. S., Schmierer, K., Giovannoni, G., & Dobson, R. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103448 · Cited by 31 · see citing works
Seki, Y., Yoshihara, Y., Nojima, K., Momose, H., Fukushi, S., Moriyama, S., Wagatsuma, A., Numata, N., Sasaki, K., Kuzuoka, T., et al. (2022) · Med · doi:10.1016/j.medj.2022.04.013 · Cited by 30 · see citing works
YangYang, Gong, X., Yang, L., Li, J., Zhang, J., Wei, L., Ye, G., Tang, Y., Jiang, Y., Li, J., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.004 · Cited by 29 · see citing works
Humoral Response to BNT162b2 Vaccine Against SARS-CoV-2 Variants Decays After Six Months
Lopera, T. J., Chvatal‐Medina, M., Flórez‐Álvarez, L., Zapata-Cardona, M. I., Taborda, N. A., Rugeles, M. T., & Hernández, J. C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.879036 · Cited by 29 · see citing works
Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development
Günl, F., Mecate-Zambrano, A., Rehländer, S., Hinse, S., Ludwig, S., & Brunotte, L. (2021) · Vaccines · doi:10.3390/vaccines9101052 · Cited by 27 · see citing works
Xu, S. S., Li, J., Wang, H., Wang, F., Yin, Z., & Wang, Z. (2023) · BMC Medicine · doi:10.1186/s12916-023-02861-3 · Cited by 27 · see citing works
Sokhansanj, B. A., Zhao, Z., & ROSEN, G. L. (2022) · Biology · doi:10.3390/biology11121786 · Cited by 27 · see citing works
Choi, J. H., Kim, Y. R., Heo, S. T., Oh, H., Kim, M.-S., Lee, H. R., & Yoo, J. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.827306 · Cited by 26 · see citing works
Wang, R., Sun, C., Ma, J., Yu, C., Kong, D., Chen, M., Liu, X., Zhao, D., Gao, S., Kou, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10050702 · Cited by 26 · see citing works
Fratev, F. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01243 · Cited by 25 · see citing works
Paternina-Caicedo, Á. J., Jit, M., Alvis‐Guzmán, N., Fernández, J. C., Hernández, J., Paz-Wilches, J., Rojas-Suárez, J. A., Castell, C. R. D., Alvis-Zakzuk, N. J., Smith, A. D., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100296 · Cited by 25 · see citing works
Genomic epidemiology of SARS-CoV-2 variants during the first two years of the pandemic in Colombia
Jiménez-Silva, C. L., Rivero, R., Douglas, J., Bouckaert, R., Villabona‐Arenas, C. J., Atkins, K. E., Gastelbondo, B., Calderón, A., Guzmán, C., la Hoz, D. E.-D., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00328-3 · Cited by 25 · see citing works
COVID-19 pandemic: the delta variant, T-cell responses, and the efficacy of developing vaccines
Biswas, B. K., Chattopadhyay, S., Hazra, S., Hansda, A. K., & Goswami, R. (2022) · Inflammation Research · doi:10.1007/s00011-022-01555-5 · Cited by 25 · see citing works
Inferring variant-specific effective reproduction numbers from combined case and sequencing data
Figgins, M. D., & Bedford, T. (2026) · eLife · doi:10.7554/elife.104802.2 · Cited by 24 · see citing works
Matsui, Y., Li, L., Prahl, M. K., Cassidy, A. G., Özarslan, N., Golan, Y., Gonzalez, V. J., Lin, C. Y., Jigmeddagva, U., Chidboy, M. A., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.157354 · Cited by 23 · see citing works
Iwamura, C., Hirahara, K., Kiuchi, M., Ikehara, S. K., Azuma, K., Shimada, T., Kuriyama, S., Ohki, S., Yamamoto, E., Inaba, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2203437119 · Cited by 23 · see citing works
Self-citationConvalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update
Chavda, V. P., Bezbaruah, R., Dolia, S., Shah, N., Verma, S., Savale, S. S., & Ray, S. (2023) · Process Biochemistry · doi:10.1016/j.procbio.2023.01.018 · Cited by 23 · see citing works
Molecular and structural insights into SARS-CoV-2 evolution: from BA.2 to XBB subvariants
Yajima, H., Nomai, T., Okumura, K., Maenaka, K., Ito, J., Hashiguchi, T., Sato, K., Matsuno, K., Nao, N., Sawa, H., et al. (2024) · mBio · doi:10.1128/mbio.03220-23 · Cited by 22 · see citing works
Self-citationZapata-Cardona, M. I., Flórez‐Álvarez, L., Gómez-Gallego, D. M., Moncada-Díaz, M. J., Hernández, J. C., Díaz, F. J., Rugeles, M. T., Aguilar-Jiménez, W., & Zapata, W. (2022) · Iranian Journal of Microbiology · doi:10.18502/ijm.v14i3.9758 · Cited by 21 · see citing works
Duty, J. A., Kraus, T., Zhou, H., Zhang, Y., Shaabani, N., Yildiz, S., Du, N., Singh, A., Miorin, L., Li, D., et al. (2022) · Med · doi:10.1016/j.medj.2022.08.002 · Cited by 21 · see citing works
Wang, Q., Ye, S., Zhou, Z., Li, J., Lv, J., Hu, B., Yuan, S., Qiu, Y., & Ge, X. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28116 · Cited by 21 · see citing works
Álvarez-Díaz, D. A., Muñoz, A. L., Tavera-Rodríguez, P., Herrera-Sepúlveda, M. T., Ruiz-Moreno, H. A., Laiton‐Donato, K., Franco-Muñoz, C., Peláez‐Carvajal, D., Cuellar, D., Muñoz-Suarez, A. M., et al. (2022) · Vaccines · doi:10.3390/vaccines10020180 · Cited by 20 · see citing works
Uriu, K., Cárdenas, P., Muñoz, E. B., Barragán, V., Kosugi, Y., Shirakawa, K., Takaori‐Kondo, A., Ito, J., Yamasoba, D., Kimura, I., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac053 · Cited by 20 · see citing works
Self-citationCOVID-19 Genetic Variants and Their Potential Impact in Vaccine Development
Giau, V. V., Bagyinszky, E., & An, S. S. A. (2022) · Microorganisms · doi:10.3390/microorganisms10030598 · Cited by 20 · see citing works
Chang, M., Ke, H., Coherd, C. D., Wang, Y., Mashima, K., Kastrunes, G. M., Huang, C., & Marasco, W. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104025 · Cited by 20 · see citing works
Guo, D., Duan, H., Cheng, Y., Wang, Y., Hu, J., & Shi, H. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00074-3 · Cited by 17 · see citing works
Zhou, H., Ni, W., Huang, W., Wang, Z., Cai, M., & Sun, Y.-C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.834942 · Cited by 17 · see citing works
Investigating SARS-CoV-2 breakthrough infections per variant and vaccine type
Dingemans, J., van der Veer, B. M. J. W., Gorgels, K. M. F., Hackert, V., Hensels, A. Y. J., den Heijer, C. D. J., Hoebe, C. J. P. A., Savelkoul, P. H. M., & van Alphen, L. B. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1027271 · Cited by 17 · see citing works
Description of a One-Year Succession of Variants of Interest and Concern of SARS-CoV-2 in Venezuela
Jaspe, R. C., Loureiro, C. L., Sulbarán, Y. F., Moros, Z., D’Angelo, P., Hidalgo, M., Rodríguez, L., Alarcón, V., Aguilar, M., Sánchez, D., et al. (2022) · Viruses · doi:10.3390/v14071378 · Cited by 16 · see citing works
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Qian, J., Zhang, S.-C., Wang, F., Li, J., & Zhang, J. (2024) · Cell Biology International · doi:10.1002/cbin.12130 · Cited by 16 · see citing works
Virion morphology and on-virus spike protein structures of diverse SARS-CoV-2 variants
Ke, Z., Peacock, T. P., Brown, J. C., Sheppard, C., Croll, T. I., Kotecha, A., Goldhill, D. H., Barclay, W., & Briggs, J. A. G. (2024) · The EMBO Journal · doi:10.1038/s44318-024-00303-1 · Cited by 16 · see citing works
Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines
Ambrosino, D. M., Han, H. H., Hu, B. T., Liang, J. G., Clemens, R. L., Johnson, M., Siber, G. R., & Goldblatt, D. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab574 · Cited by 16 · see citing works
Delshad, M., Sanaei, M., Pourbagheri‐Sigaroodi, A., & Bashash, D. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109128 · Cited by 16 · see citing works
Evasion of Vaccine-Induced Humoral Immunity by Emerging Sub-Variants of SARS-CoV-2
Koyama, T., Miyakawa, K., Tokumasu, R., Jeremiah, S. S., Kudo, M., & Ryo, A. (2022) · Future Microbiology · doi:10.2217/fmb-2022-0025 · Cited by 15 · see citing works
Dispersion patterns of SARS-CoV-2 variants Gamma, Lambda and Mu in Latin America and the Caribbean
Gräf, T., Martínez, A. A., Bello, G., Dellicour, S., Lemey, P., Colizza, V., Mazzoli, M., Poletto, C., Cardoso, V. L. O., da Silva, A. F., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46143-9 · Cited by 15 · see citing works
Simulation of future COVID-19 epidemic by vaccination coverage scenarios in Japan
Furuse, Y. (2021) · Journal of Global Health · doi:10.7189/jogh.11.05025 · Cited by 15 · see citing works
Focosi, D., Franchini, M., Joyner, M. J., & Casadevall, A. (2022) · Vox Sanguinis · doi:10.1111/vox.13239 · Cited by 15 · see citing works
mRNA-1273 and Ad26.COV2.S vaccines protect against the B.1.621 variant of SARS-CoV-2
Darling, T. L., Ying, B., Whitener, B. M., VanBlargan, L. A., Bricker, T. L., Liang, C.-Y., Joshi, A., Bamunuarachchi, G., Seehra, K., Schmitz, A. J., et al. (2022) · Med · doi:10.1016/j.medj.2022.03.009 · Cited by 15 · see citing works
Al-Rashedi, N. A. M., Alburkat, H., Hadi, A. O., Munahi, M. G., Jasim, A., Hameed, A., Oda, B. S., Lilo, K. M., AlObaidi, L. A. H., Vapalahti, O., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267295 · Cited by 15 · see citing works
Giron, C. C., Laaksonen, A., & da Silva, F. L. B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2095305 · Cited by 15 · see citing works
Lanza, F., Monaco, F., Ciceri, F., Cairoli, R., Sacchi, M. V., Guidetti, A., Marchetti, M., Massaia, M., Arcaini, L., Krampera, M., et al. (2022) · Hematological Oncology · doi:10.1002/hon.3060 · Cited by 15 · see citing works
Rapid SARS-CoV-2 Variants Enzymatic Detection (SAVED) by CRISPR-Cas12a
Yang, J., Barua, N., Rahman, M. N., Li, C., Lo, N. W. S., Yeong, K.-Y., Tsang, T. F., Yang, X., Cheung, Y., Tsang, A. K. L., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.03260-22 · Cited by 15 · see citing works
Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 15 · see citing works
Virological characteristics correlating with SARS-CoV-2 spike protein fusogenicity
Begum, M. M., Ichihara, K., Takahashi, O., Nasser, H., Jonathan, M., Tokunaga, K., Yoshida, I., Nagashima, M., Sadamasu, K., Yoshimura, K., et al. (2024) · Frontiers in Virology · doi:10.3389/fviro.2024.1353661 · Cited by 14 · see citing works
Self-citation
- Authors
- Uriu, K., Kimura, I., Shirakawa, K., Takaori-Kondo, A., Nakada, T.-A., Kaneda, A., Nakagawa, S., & Sato, K.
- Affiliations
- The University of Tokyo (JP)
- Kyoto University (JP)
- Chiba University (JP)
- Tokai University (JP)
- Corresponding author
- Sato, Kei
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-16
- Volume
- 385
- Issue
- 25
- Pages
- 2397-2399
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8609602
- OpenAlex
- W3208271747
- Cited by
- 214
- References
- 4
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 14 · 2023: 39 · 2022: 120 · 2021: 30
- FWCI
- 16.06
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Licence
- Locations
- New England Journal of Medicine (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Japan Agency for Medical Research and Development (20fk0108451)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Keywords
- SARS-CoV-2, Mu variant, Omicron variant, neutralizing antibodies, convalescent serum, COVID-19 vaccines, vaccine-induced immunity, antibody neutralization
- MeSH terms
- COVID-19, SARS-CoV-2, BNT162 Vaccine, COVID-19 Serotherapy, Colombia, Humans, Immunization, Passive, Neutralization Tests, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
